Omnicell, Inc. (OMCL): A Bull Case Theory

We came across a bullish thesis on Omnicell, Inc. on Make Money, Make Time’s Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on OMCL. Omnicell, Inc.'s share was trading at $29.98 as of October 2nd. OMCL’s trailing P/E was 59.96 according to Yahoo Finance.

Omnicell, Inc. (OMCL) is a leader in medication management and adherence automation solutions, serving healthcare systems and pharmacies. The company began with automated dispensing cabinets that enable hospitals to safely store and dispense medications but has since expanded into cloud-based software and analytics to optimize pharmacy operations. OMCL is well positioned to benefit from the healthcare sector’s ongoing focus on efficiency and cost reduction, as well as the structural shift toward automation in hospitals and pharmacies.

Automation lies at the heart of OMCL’s strategy, with a portfolio that now includes automated dispensing systems, robotic pharmacy solutions, and workflow software designed to reduce human error in medication management. Unlike many peers, OMCL has built automation into its processes from the ground up, making it a core part of the business and culture, which provides a competitive advantage as healthcare services increasingly seek to automate historically manual workflows.

From a valuation perspective, OMCL is trading near 2016 levels, reflecting a historically cheap entry point. Analysts project modest growth through 2025–2027, with a significant EBITDA jump expected by 2028, highlighting that future performance will depend heavily on management execution. Current multiples, around 10x EBITDA, appear inexpensive but reflect the limited near-term growth outlook, making investor conviction in long-term growth crucial.

Technically, the stock sits below major moving averages but has established a multi-year support level, showing a stable base despite weak momentum. Overall, OMCL offers an attractive risk/reward profile for investors who believe in the ongoing automation trend in healthcare and the company’s ability to execute on its long-term growth potential.

Previously we covered a bullish thesis on Quipt Home Medical Corp. (QIPT) by Inflexio Research in March 2025, which highlighted its recurring revenue, strong home healthcare position, and potential upside from activist involvement and a strategic sale. The stock has appreciated approximately 14.34% since coverage. The thesis still stands as strategic sale potential remains compelling. Oliver | MMMT Wealth shares a similar perspective but emphasizes Omnicell’s automation-driven growth.

Omnicell, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 22 hedge fund portfolios held OMCL at the end of the second quarter which was 25 in the previous quarter. While we acknowledge the potential of OMCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.